Cargando…
Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial
OBJECTIVE: To evaluate whether the addition of colchicine to standard of care (SOC) results in better outcomes in hospitalized patients with COVID-19. DESIGN: This interventional, multicenter, randomized, phase 2 study, evaluated colchicine 1.5 mg/day added to SOC in hospitalized COVID-19 patients (...
Autores principales: | Perricone, Carlo, Scarsi, Mirko, Brucato, Antonio, Pisano, Paola, Pigatto, Erika, Becattini, Cecilia, Cingolani, Antonella, Tiso, Francesco, Prota, Roberto, Tomasoni, Lina Rachele, Cutolo, Maurizio, Tardella, Marika, Rozza, Davide, Zerbino, Carlo, Andreoni, Massimo, Poletti, Venerino, Bartoloni, Elena, Gerli, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618432/ https://www.ncbi.nlm.nih.gov/pubmed/36396522 http://dx.doi.org/10.1016/j.ejim.2022.10.016 |
Ejemplares similares
-
Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
por: Perricone, Carlo, et al.
Publicado: (2020) -
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
por: Perricone, Carlo, et al.
Publicado: (2020) -
Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections
por: Perricone, Carlo, et al.
Publicado: (2021) -
Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future
por: Bursi, Roberto, et al.
Publicado: (2021) -
The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.
por: Piantoni, Silvia, et al.
Publicado: (2020)